Advertisement

Diabetologia

, Volume 61, Issue 12, pp 2549–2560 | Cite as

Circulating prolactin concentrations and risk of type 2 diabetes in US women

  • Jun Li
  • Megan S. Rice
  • Tianyi Huang
  • Susan E. Hankinson
  • Charles V. Clevenger
  • Frank B. Hu
  • Shelley S. Tworoger
Article

Abstract

Aims/hypothesis

Prolactin, a multifunctional hormone, is involved in regulating insulin sensitivity and glucose homeostasis in experimental studies. However, whether circulating concentrations of prolactin are associated with risk of type 2 diabetes remains uncertain.

Methods

We analysed the prospective relationship between circulating prolactin concentrations and type 2 diabetes risk in the Nurses’ Health Study (NHS) and NHSII with up to 22 years of follow-up. Total plasma prolactin was measured using immunoassay in 8615 women free of type 2 diabetes and cardiovascular disease at baseline blood collection (NHS 1989–1990; NHSII 1996–1999) and a subset of 998 NHS women providing a second blood sample during 2000–2002. Baseline bioactive prolactin was measured in a subset of 2478 women using the Nb2 bioassay. HRs were estimated using Cox regression.

Results

A total of 699 incident type 2 diabetes cases were documented during 156,140 person-years of follow-up. Total plasma prolactin levels were inversely associated with type 2 diabetes risk; the multivariable HR comparing the highest with the lowest quartile was 0.73 (95% CI 0.55, 0.95; ptrend = 0.02). The associations were similar by menopausal status and other risk factors (pinteraction > 0.70). Additional adjustment for sex and growth hormones, adiponectin, and inflammatory and insulin markers did not significantly alter the results. The association of plasma bioactive prolactin with type 2 diabetes risk was non-significantly stronger than that of total prolactin (HR comparing extreme quartiles, 0.53 vs 0.81 among the subset of 2478 women, pdifference = 0.11). The inverse association of total prolactin with type 2 diabetes was significant during the first 9 years after blood draw but waned linearly with time, whereas for bioactive prolactin, the inverse relationship persisted for a longer follow-up time after blood draw.

Conclusions/interpretation

A normally high circulating total prolactin concentration was associated with a lower type 2 diabetes risk within 9–10 years of follow-up since blood draw in US women. Our findings are consistent with experimental evidence, suggesting that among healthy women, prolactin within the biologically normal range may play a protective role in the pathogenesis of type 2 diabetes.

Keywords

Hormone Insulin Prolactin Type 2 diabetes 

Abbreviations

AHEI

Alternative Healthy Eating Index

CVD

Cardiovascular disease

hsCRP

High-sensitivity C-reactive protein

HT

Hormone therapy

ICC

Intra-class correlation coefficient

IGFBP-3

IGF binding protein-3

IR

Insulin resistance

LOD

Limit of detection

MHI-5

Five-item Mental Health Inventory

NHS

Nurses’ Health Study

NHSII

Nurses’ Health Study II

SHBG

Sex hormone binding globin

Notes

Acknowledgements

This research was conducted using data and resources from the NHS and NHSII of the Channing Division of Network Medicine in the Department of Medicine at the Brigham and Women’s Hospital and Harvard Medical School. The authors thank the NHS and NHSII investigators for their important contributions in resource development and intellectual input.

Contribution statement

FBH and SST generated the conception and designed the study. SST, MSR, SEH and CVC collected and processed the data. JL, TH and SST analysed and interpreted the data. JL drafted the manuscript. All authors revised the manuscript critically for important intellectual content, and approved the final version of the article and submission to the journal. SST is responsible for the integrity of the work as a whole.

Funding

This study was funded by the National Cancer Institute grants UM1 CA186107, P01 CA87969, R01 CA49449, UM1 CA176726, R01 CA67262, R01 CA119139, R01 CA138580 and R01 CA163451; the National Institute of Arthritis and Musculoskeletal and Skin Diseases grant R01 AR049880; and the National Institute of Diabetes and Digestive and Kidney Diseases grants DK46200 and DK112940. JL is a recipient of the ADA-Pfizer New England Cardiovascular-Metabolic Fellowship Award (9-17-CMF-011). The funders had no role in study design, data collection, data analysis, data interpretation, the writing of the report or decision of publication of the results.

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

Supplementary material

125_2018_4733_MOESM1_ESM.pdf (400 kb)
ESM (PDF 399 kb)

References

  1. 1.
    International Diabetes Federation IDF (2017) Diabetes Atlas. Available from http://www.diabetesatlas.org/key-messages.html
  2. 2.
    Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3:e442CrossRefGoogle Scholar
  3. 3.
    Kahn SE, Cooper ME, Del Prato S (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383:1068–1083CrossRefGoogle Scholar
  4. 4.
    Huang Y, Chang Y (2014) Regulation of pancreatic islet beta-cell mass by growth factor and hormone signaling. Prog Mol Biol Transl Sci 121:321–349CrossRefGoogle Scholar
  5. 5.
    Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR (2006) Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 17:110–116CrossRefGoogle Scholar
  6. 6.
    Bernard V, Young J, Chanson P, Binart N (2015) New insights in prolactin: pathological implications. Nat Rev Endocrinol 11:265–275CrossRefGoogle Scholar
  7. 7.
    Brandebourg T, Hugo E, Ben-Jonathan N (2007) Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab 9:464–476CrossRefGoogle Scholar
  8. 8.
    Cejkova P, Fojtikova M, Cerna M (2009) Immunomodulatory role of prolactin in diabetes development. Autoimmun Rev 9:23–27CrossRefGoogle Scholar
  9. 9.
    Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev 80:1523–1631CrossRefGoogle Scholar
  10. 10.
    Terra LF, Garay-Malpartida MH, Wailemann RA, Sogayar MC, Labriola L (2011) Recombinant human prolactin promotes human beta cell survival via inhibition of extrinsic and intrinsic apoptosis pathways. Diabetologia 54:1388–1397CrossRefGoogle Scholar
  11. 11.
    Weinhaus AJ, Stout LE, Bhagroo NV, Brelje TC, Sorenson RL (2007) Regulation of glucokinase in pancreatic islets by prolactin: a mechanism for increasing glucose-stimulated insulin secretion during pregnancy. J Endocrinol 193:367–381CrossRefGoogle Scholar
  12. 12.
    Ruiz-Herrera X, de Los Rios EA, Diaz JM et al (2017) Prolactin promotes adipose tissue fitness and insulin sensitivity in obese males. Endocrinology 158:56–68PubMedGoogle Scholar
  13. 13.
    Yu J, Xiao F, Zhang Q et al (2013) PRLR regulates hepatic insulin sensitivity in mice via STAT5. Diabetes 62:3103–3113CrossRefGoogle Scholar
  14. 14.
    Park S, Kim DS, Daily JW, Kim SH (2011) Serum prolactin concentrations determine whether they improve or impair beta-cell function and insulin sensitivity in diabetic rats. Diabetes Metab Res Rev 27:564–574CrossRefGoogle Scholar
  15. 15.
    Costanza M, Binart N, Steinman L, Pedotti R (2015) Prolactin: a versatile regulator of inflammation and autoimmune pathology. Autoimmun Rev 14:223–230CrossRefGoogle Scholar
  16. 16.
    Wagner R, Heni M, Linder K et al (2014) Age-dependent association of serum prolactin with glycaemia and insulin sensitivity in humans. Acta Diabetol 51:71–78CrossRefGoogle Scholar
  17. 17.
    Wang T, Lu J, Xu Y et al (2013) Circulating prolactin associates with diabetes and impaired glucose regulation: a population-based study. Diabetes Care 36:1974–1980CrossRefGoogle Scholar
  18. 18.
    Balbach L, Wallaschofski H, Volzke H, Nauck M, Dorr M, Haring R (2013) Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes? BMC Endocr Disord 13:12CrossRefGoogle Scholar
  19. 19.
    Wang T, Xu Y, Xu M et al (2016) Circulating prolactin and risk of type 2 diabetes: a prospective study. Am J Epidemiol 184:295–301CrossRefGoogle Scholar
  20. 20.
    Retnakaran R, Ye C, Kramer CK et al (2016) Maternal serum prolactin and prediction of postpartum beta-cell function and risk of prediabetes/diabetes. Diabetes Care 39:1250–1258CrossRefGoogle Scholar
  21. 21.
    Therkelsen KE, Abraham TM, Pedley A et al (2016) Association between prolactin and incidence of cardiovascular risk factors in the Framingham Heart Study. J Am Heart Assoc 5Google Scholar
  22. 22.
    Sinha YN (1995) Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 16:354–369CrossRefGoogle Scholar
  23. 23.
    Hankinson SE, Willett WC, Manson JE et al (1995) Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 87:1297–1302CrossRefGoogle Scholar
  24. 24.
    Zhang X, Tworoger SS, Eliassen AH, Hankinson SE (2013) Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat 137:883–892CrossRefGoogle Scholar
  25. 25.
    Tworoger SS, Sluss P, Hankinson SE (2006) Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 66:2476–2482CrossRefGoogle Scholar
  26. 26.
    Tworoger SS, Eliassen AH, Zhang X et al (2013) A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res 73:4810–4819CrossRefGoogle Scholar
  27. 27.
    Kotsopoulos J, Tworoger SS, Campos H et al (2010) Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses’ Health Studies. Cancer Epidemiol Biomark Prev 19:938–946CrossRefGoogle Scholar
  28. 28.
    Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE (2004) Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 64:6814–6819CrossRefGoogle Scholar
  29. 29.
    Tworoger SS, Eliassen AH, Sluss P, Hankinson SE (2007) A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 25:1482–1488CrossRefGoogle Scholar
  30. 30.
    Tworoger SS, Rice MS, Rosner BA, Feeney YB, Clevenger CV, Hankinson SE (2015) Bioactive prolactin levels and risk of breast cancer: a nested case-control study. Cancer Epidemiol Biomark Prev 24:73–80CrossRefGoogle Scholar
  31. 31.
    Heidemann C, Sun Q, van Dam RM et al (2008) Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 149:307–316CrossRefGoogle Scholar
  32. 32.
    Qi L, Rifai N, Hu FB (2009) Interleukin-6 receptor gene, plasma C-reactive protein, and diabetes risk in women. Diabetes 58:275–278CrossRefGoogle Scholar
  33. 33.
    Rice MS, Tworoger SS, Rosner BA, Pollak MN, Hankinson SE, Tamimi RM (2012) Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses’ Health Studies. Breast Cancer Res Treat 136:805–812CrossRefGoogle Scholar
  34. 34.
    Schulze MB, Solomon CG, Rifai N et al (2005) Hyperproinsulinaemia and risk of type 2 diabetes mellitus in women. Diabet Med 22:1178–1184CrossRefGoogle Scholar
  35. 35.
    Okereke OI, Pollak MN, Hu FB, Hankinson SE, Selkoe DJ, Grodstein F (2008) Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes. Psychoneuroendocrinology 33:455–461CrossRefGoogle Scholar
  36. 36.
    Arroyo C, Hu FB, Ryan LM et al (2004) Depressive symptoms and risk of type 2 diabetes in women. Diabetes Care 27:129–133CrossRefGoogle Scholar
  37. 37.
    Manson JE, Rimm EB, Stampfer MJ et al (1991) Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 338:774–778CrossRefGoogle Scholar
  38. 38.
    National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039–1057CrossRefGoogle Scholar
  39. 39.
    Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(Suppl 1):S5–S20Google Scholar
  40. 40.
    McCullough ML, Feskanich D, Stampfer MJ et al (2002) Diet quality and major chronic disease risk in men and women: moving toward improved dietary guidance. Am J Clin Nutr 76:1261–1271CrossRefGoogle Scholar
  41. 41.
    Song M, Hu FB, Wu K et al (2016) Trajectory of body shape in early and middle life and all cause and cause specific mortality: results from two prospective US cohort studies. BMJ 353:i2195CrossRefGoogle Scholar
  42. 42.
    Rosner B (1983) Percentage points for a generalized ESD many-outlier procedure. Technometrics 25:165–172CrossRefGoogle Scholar
  43. 43.
    Rosner B, Cook N, Portman R, Daniels S, Falkner B (2008) Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 167:653–666CrossRefGoogle Scholar
  44. 44.
    Daimon M, Kamba A, Murakami H et al (2017) Association between serum prolactin levels and insulin resistance in non-diabetic men. PLoS One 12:e0175204CrossRefGoogle Scholar
  45. 45.
    Newey PJ, Gorvin CM, Cleland SJ et al (2013) Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med 369:2012–2020CrossRefGoogle Scholar
  46. 46.
    Berinder K, Nystrom T, Hoybye C, Hall K, Hulting AL (2011) Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 14:199–207CrossRefGoogle Scholar
  47. 47.
    Majumdar A, Mangal NS (2013) Hyperprolactinemia. J Hum Reprod Sci 6:168–175CrossRefGoogle Scholar
  48. 48.
    Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE (1995) Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomark Prev 4:649–654Google Scholar
  49. 49.
    Lawson DM, Sensui N, Haisenleder DH, Gala RR (1982) Rat lymphoma cell bioassay for prolactin: observations on its use and comparison with radioimmunoassay. Life Sci 31:3063–3070CrossRefGoogle Scholar
  50. 50.
    Tanaka T, Shiu RP, Gout PW, Beer CT, Noble RL, Friesen HG (1980) A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum. J Clin Endocrinol Metab 51:1058–1063CrossRefGoogle Scholar
  51. 51.
    Schernhammer ES, Tworoger SS, Eliassen AH et al (2007) Body shape throughout life and correlations with IGFs and GH. Endocr Relat Cancer 14:721–732CrossRefGoogle Scholar
  52. 52.
    Moldrup A, Petersen ED, Nielsen JH (1993) Effects of sex and pregnancy hormones on growth hormone and prolactin receptor gene expression in insulin-producing cells. Endocrinology 133:1165–1172CrossRefGoogle Scholar
  53. 53.
    Sorenson RL, Brelje TC (1997) Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm Metab Res 29:301–307CrossRefGoogle Scholar
  54. 54.
    Tovar S, Dieguez C (2014) Prolactin and energy homeostasis: pathophysiological mechanisms and therapeutic considerations. Endocrinology 155:659–662CrossRefGoogle Scholar
  55. 55.
    Jones AG, Hattersley AT (2013) The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 30:803–817CrossRefGoogle Scholar
  56. 56.
    Polonsky KS, Rubenstein AH (1984) C-peptide as a measure of the secretion and hepatic extraction of insulin: pitfalls and limitations. Diabetes 33:486–494CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Jun Li
    • 1
    • 2
  • Megan S. Rice
    • 3
  • Tianyi Huang
    • 1
    • 4
  • Susan E. Hankinson
    • 2
    • 4
    • 5
  • Charles V. Clevenger
    • 6
  • Frank B. Hu
    • 1
    • 2
    • 4
  • Shelley S. Tworoger
    • 2
    • 4
    • 7
  1. 1.Department of NutritionHarvard T.H. Chan School of Public HealthBostonUSA
  2. 2.Department of EpidemiologyHarvard T.H. Chan School of Public HealthBostonUSA
  3. 3.Clinical and Translational Epidemiology Unit, Department of MedicineMassachusetts General HospitalBostonUSA
  4. 4.Channing Division of Network Medicine, Department of MedicineBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA
  5. 5.Department of Biostatistics and EpidemiologyUniversity of Massachusetts AmherstAmherstUSA
  6. 6.Department of PathologyVirginia Commonwealth UniversityRichmondUSA
  7. 7.Department of Cancer EpidemiologyH. Lee Moffitt Cancer Center and Research Institute, Inc.TampaUSA

Personalised recommendations